

Supplementary Table S1 Online analysis website

website	URL
GEPIA	http://gepia.cancer-pku.cn/
Ensembl	http://grch37.ensembl.org/index.html
UCSC	http://genome.ucsc.edu/
CPC2	http://cpc2.gao-lab.org/
CPAT	http://lilab.research.bcm.edu/
Mirdb	http://mirdb.org/
LncBase	http://carolina.imis.athena-innovation.gr/diana_tools/
Starbase	http://starbase.sysu.edu.cn/starbase2/index.php
Targetscan	http://www.targetscan.org/vert_72/
TCGA-LIHC	https://portal.gdc.cancer.gov/

Supplementary Table S2 Primer sequences, siRNAs and shRNA used in this study.

Primer name		Sequence (5'-3')
RP11-620J15.3	F	ACGGTGTTCTGGGAGGAGTT
	R	TATCTCTGCCTCTCCCGCTA
miR-326	F	CATCTGTCTGTTGGGCTGGA
	R	AGGAAGGGCCCAGAGGCG
GPI	F	CAAGGACCGCTTCAACCACTT
	R	CCAGGATGGGTGTGTTTGACC
ALDOA	F	CATTCTGGCTGCGGATGAGTCT
	R	CACACGGTCATCAGCACTGAAC
LDHA	F	CTGGGAGTTCACCCATTAAGCT
	R	CAGGCACACTGGAATCTCCAT
TP1	F	AGTGACTAATGGGGCTTTTACTG
	R	GCCCAATCAGCTCATCTGACTC
ENO1	F	ATGTCTATTCTCAAGATCCATGCCAGG
	R	CTACTTGGCCAAGGGGTTTCTGAAG
SLC2A1	F	GGCCAAGAGTGTGCTAAAGAA
	R	ACAGCGTTGATGCCAGACAG
β -Actin	F	ATCATGTTTGAGACCTTCAACA
	R	CATCTCTTGCTCGAAGTCCA
GAPDH	F	CCCATCACCATCTTCCAGGAG
	R	GTTGTCATGGATGACCTTGGC
U6	F	CGCTTCGGCAGCACATATAC
	R	CAGGGGCCATGCTAATCTT
TBP	F	CCGGAATCCCTATCTTTAGTCC
	R	GCCTTTGTTGCTCTTCCAAAAT
RP11-620J15.3-CHIP	F	GTGAAGCGATAAGACGCACG
	R	CGCAGATAACGGTCAATCGC
shNC		ATCTGCCTTCGAGCCACGT
RP11-620J15.3-sh1		AAUAUCUCUGCCUCUCCCGUU
RP11-620J15.3-sh2		UUUAGCACAUUCUCUGUUUUU
RP11-620J15.3-sh3		UGUCUGUAUGUUCUUUAGCUU
siNC		UUCUCCGAACGUGUCACGU
TBP-si1		AAUAUCUCUGCCUCUCCCGUU
TBP-si2		UUUAGCACAUUCUCUGUUUUU

Supplementary Table S3 Primary antibodies used in this study

Antigens	Manufacturer	Catalog Number	Application
GPI	Proteintech	15171-1-AP	1:1000 for WB;
TBP	Proteintech	66166-1-Ig	1:10000 for WB;
β -actin	Proteintech	66009-1-Ig	1:1000 for WB;
IgG	Servicebio	GB23303	IP
IgG	Servicebio	GB23301	IP
AGO-2	Proteintech	66720-1-Ig	IP

Supplementary Table S4 Correlation between clinicopathological features and RP11-620J15.3 expression in HCC tumor tissues.

Characteristics		Number	RP11-620J15.3 expression		P value
			High	Low	
Gender	Male	35	17	18	<i>0.8217</i>
	Female	45	23	22	
Age	<65	37	19	18	<i>0.8226</i>
	≥65	43	21	22	
HBV infection	No	31	12	19	<i>0.1082</i>
	Yes	49	28	21	
AFP	≤400 (μg/L)	33	15	18	<i>0.4957</i>
	>400 (μg/L)	47	25	22	
Tumor size	≤5cm	39	14	25	<i>0.01388*</i>
	>5cm	41	26	15	
TNM staging	I-II	39	17	22	<i>0.2634</i>
	III-IV	41	23	18	
Lymph node metastasis	Absent	51	22	29	<i>0.1035</i>
	Present	29	18	11	
BCLC stage	Low	33	13	20	<i>0.1119</i>
	High	47	27	20	
PVTT	NO	45	18	27	<i>0.04252*</i>
	YES	35	22	13	

*The expression of RP11-620J15.3 were compared between the tumor tissue and the normal tissue. BCLC, Barcelona Clinic Liver Cancer; PVTT, portal vein tumor thrombus. Bold italics indicate statistically significant values. *P<0.05